Friday, June 4, 2021

AVK, BOX, CSWC, CVA, ETSY, FFHPRI:CA, FIE:CA, GIS, GMTA, GOOD, HOPE, K, KEY, OGE, REYN, SWZ, TAK, TPVG, XRE:CA

Economy

Employment Situation Summary: The BLS reported that the economy added 559K jobs last month. The consensus according to FactSet was at 650K. The unemployment rate declined .3% to 5.8%. The average workweek was unchanged at 34.9 hours. Average hourly earnings increased by 14 cents to $30.33, or .5% month-over-month, following a 21 cent increase in April. The BLS noted that this surge in compensation suggests "that the rising demand for labor associated with the recovery from the pandemic may have put upward pressure on wages."  

ISM's index for manufacturing rose to 61.2 last month, up from 60.7 in April. The new orders component increased to 67 from 64.3 in April. Manufacturing accounts for about 12% of the U.S. economy. 

ADP private payrolls May 2021: +978K

Costco is seeing inflation abound, impacting a slew of consumer products

U.S. manufacturers blame Trump-era tariffs for inflation’s rise - MarketWatch

As of 12:35 E.D.T. today, the ten-year treasury yield has declined by 7 basis points to 1.55+%. U.S. 10 Year Treasury Note Overview | MarketWatch Regional bank stocks are treading down: 

SPDR S&P Regional Banking ETF (KRE): $70.08 - $.76 or 1.08% as of $12.35 E.D.T.

+++

Markets and Market Commentary

P/E & Yields

Shiller PE Ratio

Shiller PE Ratio - 150 Year Chart | Longtermtrends

Market Cap to GDP-The Buffett Indicator-Updated Historical Chart | Longtermtrends

The Q Ratio and Market Valuation: May Update - dshort - Advisor Perspectives (6/3/21)(2.98 compared to a 2.15 high in 1999)

Our Ultimate Stock-Pickers' Top 10 High-Conviction Purchases | Morningstar

Pembina (PBA) and Inter Pipeline to Combine Highly Integrated and Complementary Businesses to Accelerate Long-term Strategic Plan

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study - June 3, 2021 - Zacks.com

Selected Earnings Reports Owned Stocks

Aegon (AEG) reports first-quarter 2021 results (operating result increases 20% to €431M with the consensus estimate at €378M; free cash flow = €75M)

Brookfield Asset Management (BAM) reports $6.4 billion of Investment Gains in First (Net income attributable to common shareowners = $1.235B or $.77 per share with FFO per share at $1.8)

Power Corporation (PWCEF) Reports First Quarter 2021 Financial Results (Reported E.P.S. = C$.82; adjusted E.P.S. at C$1.16, up from C$.62 in the 2020 1st quarter; PWCEF is the symbol for the USD priced shares that trade on the pink sheet exchange)

Scientific Applications International (SAIC) Announces First Quarter of Fiscal Year 2022 Results (GAAP E.P.S. at $1.38; Adjusted E.P.S. = $1.94 with the consensus at $1.512 per Fidelity; revenues up 7% Y-O-Y to $1.878B; free cash flow up 4% to $164M; raises fiscal 2022 adjusted E.P.S. guidance to $6.15 to $6.4 from $6.00 to $6.25; the 2022 fiscal year ends 1/28/22)

Salesforce (CRM) Announces Strong First Quarter Fiscal 2022 Results (GAAP E.P.S. at $.50; non-GAAP E.P.S. = $1.21 with the consensus at $.885 per Fidelity; mark-to-market accounting of the company’s strategic investments benefited GAAP diluted earnings per share by $0.23 based on a U.S. tax rate of 25% and non-GAAP diluted earnings per share by $0.24 based on a non-GAAP tax rate of 21.5%; revenues at $5.96B, up 23%; "Cash generated from operations for the first quarter was $3.23 billion, an increase of 74% year-over-year. Total cash, cash equivalents and marketable securities ended the first quarter at $15.02 billion."; second-quarter fiscal year revenue guidance between $6.22B to $6.23B, up about 21% Y-O-Y)  

Splunk Inc. (SPLK) Announces Fiscal First Quarter 2022 Financial Results (GAAP E.P.S. -$2.89; Non-GAAP at -$.91; cloud revenue up 73% to $194M; total revenues = $502M, up 16% Y-O-Y; Cloud "ARR" at $877M; Total ARR +$2.47B, up 38% Y-O-Y; "Total Annual Recurring Revenue (“Total ARR”) represents the annualized revenue run-rate of active cloud services, term license and maintenance contracts at the end of a reporting period. Cloud Annual Recurring Revenue (“Cloud ARR”) represents the annualized revenue run-rate of active cloud services contracts at the end of a reporting period. Each contract is annualized by dividing the contract value by the number of days in the contract term and then multiplying by 365.")

TransAlta Renewables (TRSWF) Reports First Quarter 2021 Results and Closes Acquisition of 303 MW Asset Portfolio including 274 MW of Wind Capacity from TransAlta ($ amounts in CADs; cash available for distribution "of $90 million or $0.34 per share in the first quarter, in line with the same period in 2020; dividends paid in the quarter = $.23, paid in monthly installments; renewal energy production 1,109 GWh)

+++

Interest Payments Received 6/1/21-Fidelity Taxable

I am still receiving a decent amount of bond interest payments notwithstanding the now frequent issuer optional redemptions. Corporate bond interest payments will be down significantly this year compared to 2020. 

Municipal Bond Interest Payments this account: $784.38

Corporate Bond Interest Payments this account-All 1 Bond Lots:  $100.63  

Entergy Subsidiaries: First Mortgage Bonds


++

Schwab Reclaims Partial Roche Dividend Tax

I do not recall Schwab reclaiming an overpayment of a foreign dividend tax. 

When I initially received the Roche 2021 annual dividend, Switzerland withheld 35% as a dividend tax ($2.14 tax ÷ $6.1 dividend = 35% tax rate). 

The Switzerland-U.S. tax treaty provides that no more than a 15% tax can be collected from a dividend paid to a U.S. citizen.  However, to claim that treaty right initially, the broker must assert this treaty right "at the source". There is also a process to assert the treaty tax limit subsequent to the payment, which is what Schwab did here by reclaiming $1.26 of the $2.14 previously paid. The reclaimed $1.26 required a 4 cent upward adjustment in the ADR management fee, a recalculation that could have been avoided by asserting the treaty right at the source.       

I own RHHBY in two taxable accounts (15 shares in my Fidelity account with a $40.86 AC per share; 10 shares in my Schwab account with a $41.14 AC per share).

Fidelity also did a reclamation: 


 
++

Majorie Taylor Greene (R-GA): “You know, Nazis were the National Socialist Party. Just like the Democrats are now a national socialist party.”  I am confident that Ms. Greene would be viewed as a qualified candidate to teach history in her congressional district. 

Texas Republicans finalize a bill that would enact stiff new voting restrictions and make it easier to overturn election results - The Washington PostTexas Republicans unveil sweeping voting restrictions bill - CBS News  The Texas Republicans are starting to see their power fade some and are taking steps to preserve their power position through anti-democratic means. 

The GOP Now Stands for Nothing Other Than Its Right to Rule- The Atlantic

Michael Flynn Says Coup Like in Myanmar 'Should Happen' in America The primary threat to America's democracy and freedoms comes from within. And, there is no question IMO that this threat is growing exponentially. 74.2+M Americans voted to give the most powerful enemy to America's democracy since the nation's founding another 4-year term as President.   

Texas voting bill goes further than predecessors in limiting Black churches - The Washington Post The Texas republicans do not want blacks to meet for Sunday service and then proceed en masse to vote which is a historical way for blacks to organize and get out the vote. 

Opinion | A frantic warning from 100 leading experts: Our democracy is in grave danger - The Washington Post, referencing this document: Statement of Concern 

Observers of Arizona’s GOP-led election audit document security breaches, prohibited items on counting floor - The Washington Post

Paul Allard Hodgkins, 38, pleads guilty to a felony in capitol riot - The Washington Post He was photographed wearing Trump 2020 garb. In Trump's America, everyone who stormed the Capital wearing Trump emblazoned clothing, MAGA hats, and waving Trump flags were in fact Antifa members in disguise who created havoc inside the nation's capital in order to embarrass Don the Authoritarian. In TrumpWorld, the Antifa members even went so far as to have pro-Trump media posts spanning years and prior attendances at Trump rallies dressed in Trump MAGA hats and garb to further their deception. 

66 percent of GOP want Trump to run for reelection: poll | TheHill

+++

1. Canadian ETFs

The SEC has banned new purchases of Canadian ETFs that do not file prospectuses with that agency. The prospectuses, which almost no one reads, are available for anyone interested in reviewing them at the sponsors' websites. Since I was no longer allowed to buy shares, I decided to sell all of my positions but was not allowed to do so online by IB for about 5 months.   

A. Eliminated FIE:CA-Sold 600 at C$7.81


Quote:  iShares Canadian Financial Monthly Income ETF

Profit Snapshot: +C$883.5


Recent Buy DiscussionsItem # 3 Added 100 FIE:CA at C$5.05 and 100 at C$5.47 (5/9/20 Post)Item # 1 Bought 100 FIE:CA at C$6.74 (9/21/19 Post)Item # 1 Added 100 FIE:CA at C$6.84 .(7/13/19 Post)Item # 2. Bought 100 FIE:CA at C$6.92 (4/7/19 Post)  

Dividend: Monthly at C$.04 per share

Previous Round-TripsItem # 5. Sold 300 FIE:CA at C$7.64 (11/26/17 Post)(profit snapshot = C$160);  Item # 5. Sold 300 FIE:CA at C$7.64 (11/26/17 Post) (profit snapshot=C$35)(contains snapshots of prior round-trip trades= USD$391.32 for 1500 shares and US$58.07 for 300 shares; C$166 for 200 shares); Item # 2.C. Sold 100 FIE:CA at C$7.33 (12/11/19 Post)(profit snapshot = C$3) Some of the profit snapshots are in USDs since the broker converted the CAD profit into USDs.

FIE:CA Profits Realized to Date:
US$449.39 (converted from CADs by Fidelity)
C$1,087.5 (IB trades) 

B. Eliminated XRE:CA-Sold 100 at C$18.45


Quote: XRE | iShares S&P/TSX Capped REIT Index ETF Overview

Sponsor's Website: iShares S&P/TSX Capped REIT Index ETF | XRE

Number of Holdings: 20

Top 10 Holdings as of 5/27/21: 

Of those holdings, I currently own Riocan and Dream Industrial. My largest position is 1,000 Northwest Healthcare units (600 priced in CADs and 400 priced in USDs) which had a 3.42% weighting in this ETF as of 5/27.

Expense Ratio: .61

Last DiscussedItem # 3. Bought 100 XRE:CA at C$15.12(8/8/20 Post) 

Profit Snapshot: +C$331



Dividends: Monthly at a variable rate. All dividends were paid in CADs. 

2. Canadian Reset Equity Preferred Stocks

A. Eliminated FFHPRI-Sold 200 at C$18.71:

Quote: FFH-PI.TO 

Security: Reset Equity Preferred Stock 

Par Value: C$25

Coupon: 2.85% spread to the 5 year Canadian Bond, resets every five years

Last Reset: December 2020  

Issuer: Fairfax Financial Holdings Ltd. (Canada: Toronto) 

Profit Snapshot: +C$433.5


Last DiscussedItem # 1. Added 50 FFHPRI:CA at C$16.55 (1/2/20 Post) 

I discussed the reason for this elimination in a 5/23/21 comment

Reset December 2020 at a 3.327% coupon: 

Next Reset: December 2025

Dividends: Paid quarterly and cumulative 

3. Small Ball

Baseball analogy-Small ball (baseball)-Wikipedia  

The underlying rationale for the small ball trading strategy is risk mitigation in what I view as a dicey stock market whose parabolic rise has been fueled by (1) unprecedented money creation; (2) central bank suppression of interest rates far below the inflation rate through extraordinarily abnormal monetary policies continued now for over a decade; (3) extreme levels of U.S. government deficit spending, and (4) spending rapidly increasing amounts of borrowed money by U.S. households and corporations. 

It is only a question of time until those stimulus measures will no longer be available or will have to be reduced to a level that will not be sufficient to move the needle. Until that becomes apparent, I will continue to maintain a relatively low stock allocation, focused primarily on income generation and some harvested capital gains.  

Small Ball Rules:

(1) Each purchase has to be at the lowest price in the chain; or has to lower my average cost per share; 

(2) Purchases are made in small lots, using commission-free trades;

(3) On price pops, I will consider selling my highest cost shares at a profit, no matter how small;

(4) Some positions will be eliminated altogether on price pops when the goal is achieved; 

(5) Shares purchased with dividends may be sold when it is profitable to do so and the share price is outside my consider to buy range.  

The overreaching goal is to reduce risk through a controlled and disciplined trading strategy that realizes gains, particularly by selling the highest cost lots that reduce my average cost per share, increasing my dividend yield.  

The corollary is to buy the dips, particularly during extreme volatility events that would be associated with major declines in stocks.   

Another aspect is selling fractional shares bought with dividends in order to harvest the original dividend amount plus a small profit on the shares. I am doing that regularly now, having turned off the dividend reinvestment option in virtually all stocks that I own. 

The primary known threats to the stock market are inflation and valuations. The primary assumption is that the extraordinary stimulus measures outlined above can continue indefinitely or that the economy will experience robust growth when they have to be withdrawn.  

A. Bought 1 ETSY at $159.7


Quote: ETSY 

Etsy - Shop for handmade, vintage, custom, and unique gifts for everyone

ETSY Analyst Estimates | MarketWatch

I view ETSY as overvalued using traditional valuation measures. The consensus non-GAAP E.P.S. estimate for 2021 is currently at $3.01 and at $5.24 in 2023. Using the $3.01 non-GAAP estimate for 2021, the current P/E is 53.06 at $159.7, which is too high IMO, but falls to 30.48 by 2023 using the $5.24 consensus estimate. 

If the company can continue that projected growth rate for several years, it will then justify its current P/E multiple based on a $159.7 stock price IMO, but that growth will not be fueled by mask sales which drove the stellar 2020 growth rate unless the pandemic roars back. 

And investors have shown a willingness in recent years to assign higher multiples for growth stocks than in the past, justified in large part by low inflation and interest rates and by overall sluggish earnings and revenue growth in many industries. 

ETSY SEC Filings

10-Q for the Q/E 3/31/21 

2020 Annual Report 

Recent News: Etsy is buying fashion resale app Depop for $1.62 billion (6/2/21); SEC Filed Press Release 

Key Operating Metrics 2018-2020 (page 75 Annual Report): 

I mentioned this purchase in a  5/12/21 comment

Last Earnings Report (Q/E 3/31/21): SEC Filed Press Release 

GMS = Gross Merchandise Sales 

Adjusted E.P.S. = $1.00 vs. consensus at $.88

Revenues: $550.6M vs. consensus at $530.4M

GMS up 132% to $3.1B.

Ended the quarter with 90.6M active buyers, up 90%. 

The Stock Jocks responded negatively to this report due to ETSY's forward guidance. 

For the current quarter, ETSY forecasted revenue growth of 15% to 25% ($493M to $536M) compared to triple-digit growth rates in the prior 4 quarters.  

The company experienced a significant bump in revenues and profits related to mask sales. The question is whether ETSY can convert the mask buyers into regular buyers of other products.  

The stock price peaked at $251.86 (3/2/21). The stock had started to drift down before the earnings report due to concerns about future growth prospects.  The stock closed at $184.57 on 5/5 prior to the earnings announcement and at $157.68 the next day. ETSY Historical 

Broker Report (available to Schwab customers): 

S & P (5/30/21): 3 stars with a 12 month PT of $180, cut $55 from the prior estimate.

Other Brokers Reports (unavailable to me): 

Citigroup (5/10/21): Reduces PT to $245 from $260, maintains buy rating.   

Stifel (5/7/21): Raises to buy with a $205 PT. 

Oppenheimer (5/5/21): Maintains buy with a $200 PT reduced from $240.

Keybanc: Reaffirmed neutral rating, previously downgraded from outperform. Etsy Falls as Long-Time KeyBanc Bull Turns Neutral - TheStreet (4/26/21)

Morgan Stanley: Maintained underweight.  

Etsy Slides as Analysts Weigh Earnings Beat, Soft Guidance - TheStreet

Purchase Restriction: 1 share lots with each subsequent purchase at the lowest price in the chain. 

Maximum Position: 10 shares

B. Pared GIS in Fidelity Taxable account-Sold 1.592  at $64.42


Quote: General Mills Inc

GIS SEC Filings

General Mills: Brands overview

General Mills Inc. Interactive Charts

GIS Analyst Estimates

10-Q for the Q/E 2/28/21

Profit Snapshot: +$8.09 (5/13 sale only)

Fidelity's fractional engine broke up a 1 share lot purchase made on 12/30/20 into 2 lots.   

New Average cost per share this account: $56.13 (60 shares)

Snapshot Intraday on 5/13/21 after pare

Dividend: Quarterly at $.51 per share 

General Mills, Inc. - Stock Information

I am continuing to reinvest the dividend but will sell the shares purchased with dividends at a profit when and if I can do so. In this pare, the .592 fractional share was purchased with 2 dividend payments including the one paid on 4/29/21. I currently have no fractional shares purchased with dividends.  

Yield at $56.13: 3.63%

Last Ex-Dividend Date: 4/8/21

I discussed the last earnings report in this post: Item # 1.A. Pared GIS in Fidelity Taxable-Sold 4 at $61.37 (4/17/21 Post)General Mills Reports Fiscal 2021 Third-Quarter Results

Last Buy Discussions Item # 1.G. Added to GIS in Fidelity Taxable Account-Bought 5 at $55.9; 5 GIS at $55.5; 5 at $55.2; 5 at $54.9; 5 at $54.5; 5 at $54 (2/6/21 Post)Item # 1.A. and 1.B. Started GIS in Schwab Taxable account and Added to GIS in Fidelity Taxable Account (1/9/21 Post)Item # 1.F. Bought 2 GIS at $47.88 (3/28/20 Post)Item # 5 A. Bought 2 GIS at $40.25, 2 at $39.45, 10 at $38.3 and 5 at $36.75-Used Commission Free Trades (12/29/18 Post) 

Other Sell DiscussionsItem # 1.A. Eliminated GIS-Sold 27+ at $54.86 (3/21/20 Post)(profit snapshot = ($426.37); Item # 1.A. Sold 13 GIS at $55.02-Used Commission Free Trade (8/17/19 Post)(profit = $134.13); Item 1.B. Sold Highest Cost GIS lots at $51.69 (4/7/2019 Post)Item #2.A. Sold 10 GIS at $56.18-Used Commission Free Trade  (12/21/17 Post) Snapshots of 2007 through 2017 round-trip trades can be found in Item 1.B. The largest single gain was $1,285.51 realized on a 52 share lot in 2016. There have not yet been any realized losses.  

C. Pared K in Fidelity Taxable Account-Sold 1 at $67.93


Quote: Kellogg Co. (K)

Kellogg Co. Analyst Estimates | MarketWatch

SEC Filings

Kellogg Company | Our Brand Portfolio

Annual Report for the F/Y Ending 1/2/21

Investment Categories: Bond Substitute/Dividend Growth (recently sluggish)

I am selling my highest cost lots. 

Last Buy DiscussionsItem # 1.L. Added to Kellogg (K)-Bought 2 at $61; 1 at $60.5; 1 at $59.9; 1 at $59.4; 1 at $58.8; 1 at $58; 1 at $57.6 (1/30/21 Post)Item # 3.D. Added to Kellogg-Bought 4 at $62.7; 2 at $62.44; 2 at $61.3 (12/19/20 Post)(last substantive buy discussion); Item # 1 Bought 50 Kellogg at $55.44 and 10 at $54.68-Used Commission Free Trades (7/20/19 Post)

Profit Snapshot: $5.02 (5/13/21 sale only)

Average cost per share this account = $60.66 (23+ shares) 

Snapshot Intraday 5/13 after pare 

Dividend: Quarterly at $.58 per share ($2.32 annually); last raised from $.57 effective for the 2021 second quarter payment. 

Dividends – Kellogg Company

Yield at New AC = 3.82%

Last Ex-Dividend: 5/28/21

Dividend reinvestment has been turned off. 

Last Earnings Report (Fiscal Q/E  4/3/21): SEC Filed Press Release


Raised Full Year Guidance: 


Last Bond Offering Prospectus (May 2021): €300M senior unsecured notes with a .5% coupon maturing in 2029. 

SU Debt Ratings: BBB/Baa2-Fixed Income - Kellogg Company

Last Sell DiscussionsItem # 1.L. Pared K-Sold 2 at $65 (4/17/21 Post)(profit snapshot = $1.57); Item # 1.B. Sold 30 K at $66.3 (3/21/20 Post)(profit snapshot = $332.32); Item # 2. Pared Kellogg- Sold  10 at $69.3 (1/8/2020 Post)(profit snapshot = $138.58); Item # 2.C. Sold 10 K at $66.3 (12/28/19 Post)(profit snapshot = $108.58); Item # 3.B. Sold 10 K at $63.95 (8/10/2019 Post)(profit snapshot = $85.08) 

The K stock purchases in 2019 were probably my first. I have owned its senior unsecured bonds. 

Kellogg (K) Realized Gains to Date: $671.15

D. Pared REYN in Schwab Taxable-Sold 5 at $31.5

Quote: Reynolds Consumer Products Inc. (REYN)

REYN Analyst Estimates | MarketWatch

SEC Filings

Website: Reynolds Consumer Products

Brands 

Investment Categories: Bond Substitute/Contrarian Value

Last Buy DiscussionsItem # 2.O. Adeed to REYN in Schwab Taxable-Bought 4 at $27.5; 5 at $27.3 (3/6/21 Post)Item # 1.Q. Added to REYN-Bought 2 at $27.9; 2 at $27.67 (2/27/21 Post)Item # 1.J. Started REYN in Schwab Taxable Account-Bought 5 at $29.95; 5 at $28.95; 2 at $28.58 (2/20/21 Post)

Profit Snapshot: +$7.75 


New Average Cost per share this account = $27.78 (20+ shares)

Snapshot Intraday 5/14/21 after pare

By selling the highest-cost lot, I reduced the AC from $28.37 to $27.78 and increased the dividend yield to 3.31% from 3.24%.    

Dividend: Quarterly at $.23 per share ($.92 annually)

Last Ex-Dividend: 5/12/21 (Sold after ex-dividend date)

Last Earnings Report (Q/E 3/31/21): Reynolds Consumer Products (REYN) Reports First Quarter 2021 Financial Results

GAAP E.P.S. at $.35, non-GAAP at $.36 with the consensus at $.364 per Fidelity; 

revenues up 4% to $757M; 

2021 guidance now at non-GAAP E.P.S. between $1.83 to $1.94 with revenue growth in the high single digits compared to $3.263B in 2020;

"the Company expects short-term earnings pressure in the second quarter, reflecting increases in commodity and logistics costs that precede price increases as well as continuing impacts from February’s storms.

E. Eliminated OGE-Sold 15 at $34.62

Quote: OGE Energy Corp

OGE SEC Filings

OGE Energy Corp. Profile | Reuters

Corporate Profile | OGE Energy Corp.

OGE Analyst Estimates | MarketWatch

Buy DiscussionItem # 1.I. Started OGE-Bought 5 at $32.15; 1 at $31.63; 4 at $31.31; 5 at $30.7; 5 at $30.31 (1/30/21 Post)

Last Sell DiscussionItem # 1.J. (4/1/21 Post) 

Profit Snapshot: $57.36  (5/14/21 sale only)

Last Earnings Report (Q/E 3/31/21): OGE Energy Corp. (OGE) reports first-quarter results

E.P.S. at $.26 with consensus at $.217 per Fidelity; 

2021 guidance: "OG&E's earnings guidance remains unchanged and is between $352 million to $373 million, or $1.76 to $1.86 per average diluted share.  Based on first-quarter 2021 results, including the impacts of the 2021 February extreme cold weather event and strong mitigation efforts, OG&E currently projects full year results in the lower half of the range"

F. Pared GOOD-Sold 2.197 shares at $20.8 and 2.352 at $20.84



Quote: Gladstone Commercial Corp. (GOOD)

"Gladstone Commercial Corporation is a REIT that invests in single tenant and anchored multi-tenant net leased industrial and office properties nationwide." About Gladstone Commercial Corporation 

As of 5/10/21, GOOD owned 120 properties totaling 15.5 million square feet of rentable space, located in 27 states. The occupancy rate was at 95.5%. 

Properties 

SEC Filings

2020 Annual Report 

Investment Category: Equity REIT Common and Preferred Stock Basket Strategy

Last Buy Discussions: Item # 2.J. Added 2 GOOD at $13.35 (5/30/20 Post)

I eliminated all shares purchased with monthly dividend payments.  

Profit Snapshot:  +$20.77 

New Average Cost per share = $13.19  (58 shares)

Snapshot Intraday on 5/26/21 after second pare

These pares reduced the AC per share from $13.5. 

Dividend: Monthly at $.1215 ($1.46 rounded annually)

Yield at New AC per share = 11.05%

Next Ex-Dividend: 6/17

Last Ex-Dividend: 5/18

Last Earnings Report (Q/E 3/31/21): 

Gladstone Commercial Corporation (GOOD) Reports Results for the First Quarter Ended March 31, 2021

FFO per share = $.40; core FFO per share at $.42; 

quarterly dividend per share = $.37545 paid in monthly installments; 

properties = 120; 

leased = 95.5%; 

collected 98% of rents in the first quarter; sold 610,383 shares of common stock for $11.3M under ATM program

Last Sell DiscussionsItem 1.M. Pared GOOD-Sold 12 at $18.72 and 10 at $19.76 (6/20/20 Post)Item # 1.C. Eliminated GOOD in Schwab Account-Sold 50+ at $20.88 and Item # 1.D. Sold Highest Cost GOOD Share in Fidelity Account at $21.36 (3/3/19 Post)

G. Bought 1 BOX at $23.38; 2 at $22.9



Quote: Box Inc. Cl A  

BOX is a new name for me. 

BOX SEC Filings 

BOX Annual Report for the F/Y Ending 1/31/21 "Box is the Content Cloud: one secure, cloud-native platform for managing the entire content journey. Content – from blueprints to wireframes, videos to documents, proprietary formats to PDFs – is the source of an organization’s unique value. Our cloud content management platform enables our customers, including 67% of the Fortune 500, to securely manage the entire content lifecycle, from the moment a file is created or ingested to when it’s shared, edited, published, approved, signed, classified, and retained. Box keeps content secure and compliant, while also allowing easy access and sharing of this content from anywhere, on any device."

BOX Analyst Estimates | MarketWatch

Box quarterly revenue tops $200 million for the first time - MarketWatch (5/28/21)

Last Earnings Report (Q/E 3/31/21): Box Reports Strong Fiscal First Quarter 2022 Financial Results 

Non-GAAP E.P.S. at $.171

Consensus at $.18 per Fidelity

H. Eliminated CSWC-Sold 20 at $24.1


Quote: 
Capital Southwest Corp.-  A BDC

5 Year Financial Data

Page 51

Management: Internal

Net Asset Value per share as of 3/31/21: $16.01, up from $15.13 as of 3/31/20, but down from $18.62 as of 3/31/2019 and $18.62 as of 3/31/2018.

Profit Snapshot: +$220


Last Buy DiscussionsItem # 1.B. Added 10 CSWC at $12.9(8/8/20 Post)Item # 4.F. Started CSWC-Bought 10 at $13.3 (6/27/20 Post)

Last Sell DiscussionItem # 1.L. Eliminated CSWC in Schwab Taxable Account-Sold 10 at $18.18 (2/27/21 Post)(profit snapshot = $59.5) I discussed the 2020 4th quarter report in that post. 

Dividend: Last Quarterly at $.53 per share includes a $.10 per share special dividend.   

CSWC  Dividend History | Nasdaq

During the F/Y ending 3/31/21, CSWC paid out $1.65 per share in regular dividends and $.40 per share in special dividends. The special dividend payments are being sourced from prior undistributed NII. As of 3/31/21, the undistributed amount amounted to $.91 per share. 

Next Ex-Dividend: 6/14/21

Last Earnings Report (4th Fiscal Quarter ending 3/31/21): SEC Filed Press Release


I. Pared SWZ-Sold 8.342 at $9.36


Quote: Swiss Helvetia Fund Inc. Overview- A CEF

Last Buy DiscussionsItem # 1.O. Averaged Up-Bought 3 SWZ  at $8.83 (3/13/21 Post)Item # 2 Bought 100 SWZ at $7.92.(7/18/20 Post)

Sponsor's Website:  SWZ Fund - Schroders

SWZ SEC Filings 

SEC Filing Holdings as of 3/31/21 

SEC Filed 2020 Annual Report 

Profit Snapshot: +$5.48 


I sold all shares purchased with dividends or otherwise that had a cost basis of $8 or higher. I turned off dividend reinvestment. 

Average cost per share this account after pare = $7.57

Snapshot Intraday 5/18/21 after pare

Data Date of 5/18/21 Trade

Closing Net Asset Value Per Share: $10.84

Closing Market Price: $9.37 

Discount: -13.56

Sourced: SWZ CEF Connect 

Discount at $7.57 AC to $10.84 NAV per share = -30.17%

Dividend History 

As of 4/30/21, the 3 largest positions were Nestle, Roche, and Novartis, accounting for 40.44% of total assets. 

J. Pared ERC-Sold 3.195 at $12.7


Quote: Wells Fargo Multi-Sector Income Fund Overview- A CEF

ERC SEC Filings 

SEC Filing: Holdings as of 1/31/21 

SEC Filed Annual Report for the F/Y ending 10/31/20 

Wells Fargo Multi-Sec Income (ERC) Quote | Morningstar (rated 3 stars)(shows ROC support for dividend payments)

I eliminated all shares that had a cost basis over $10 including all remaining shares bought with dividends. 

Dividend reinvestment has been turned off. 

Profit Snapshot: $7.08 (5/18/21 sale only)

Remaining Shares this account after pare = 40

Snapshot Intraday 5/18/21 after pare

AC per share after pare = $8.82 (40 shares)

Snapshot Intraday 5/18/21 after pare

Dividend: Monthly at a variable rate. Over the past 12 months, the dividend has fluctuated from a low of $.913 per to a high at $.0955. The dividend is supported by ROC. 

Yield at new AC = 12.52%  (assumes an average penny rate of $.092 over a 1 year period; actual results will vary)

Data as of 5/18/21 Trade

Closing Net Asset Value Per Share: $12.88

Closing Market Price: $12.72

Discount:  -1.28%

Average 5 Year Discount  = -7.74% 

Compared to this CEF's history, the -1.28% discount is abnormally low. Generally, I would eliminate a leveraged bond CEF when the discount is this low but decided to keep a few ERC shares for the dividend income.   

Leveraged: Yes at close to 28% as of 5/28/21

Junk Bond Weightings as of 3/31/21: I am uncomfortable with these weightings. 

BB: 28.4%

B: 25.22%

K. Pared CVA-Sold 13.204 at $15.07

Quote: Covanta Holding Corp. (CVA)

CVA sells the energy generated by using garbage as a fuel and will receive a tip fee for taking the garbage.  A tip fee is a charge based on the quantity of garbage received at CVA's waste-to-energy facilities. 

CVA SEC Filings;  2020 Annual Report (see page 5 for a general summary of businesses)

Waste-to-Energy - Covanta

Metals Recycling - Covanta

Home | Covanta Environmental Solutions

Total Ash Processing - Covanta

The general idea will be to gradually pare the position by selling shares that were bought at over $10 per share. I will not be selling fractional shares that have a cost basis of less than $10. Dividend reinvestment however has been turned off. 

Profit Snapshot: $4.05

Average Cost per share after pare: $13.9 (119 Shares) 

Snapshot Intraday on 5/18/21 after pare

DividendQuarterly at $.08 per share, cut from $.25 effective for the 2020 second quarter payment. This slash was largely related to the negative impacts of the pandemic. Covanta Investors-Dividends 

While the cut was understandable under the circumstances, the slash took away a major reason for owning the stock.  

Another negative is the company is over-leveraged IMO. 

CVA's senior unsecured debt is currently rated at B1/B, which is another explanation for the dividend slash. CVA 6% SU Maturing on 1/1/2027-FINRA Page Arguably, the prudent course would be to eliminate the dividend and to use the extra cash to pay down debt.

Yield at New AC: 2.3%

Next Ex-Dividend: 6/23/21

Most Recent Bond OfferingProspectus for $400M in SU Bonds maturing in 2030 (proceeds to be used to pay off 5.875% SU note maturing in 2024)

Last Earnings Report (Q/E 3/31/21): SEC Filed Press Release 

2021 Guidance:

Last Sell DiscussionItem # 1.A. Eliminated CVA in Schwab Taxable Account-Sold 70 at $12.76 and Item # 1.B. Eliminated CVA in Vanguard Taxable -Sold 44+ at $13.19 (12/19/20 Post)(profit snapshots = $67.02 and $109.65)  

CVA Realized Gains to Date: $180.72, an unsuccessful investment that required averaging down to escape with a profit. 

L. Eliminated BZH-Sold 5 at $23.05



Quote: Beazer Homes USA Inc. (BZH)- Homebuilder

BZH Analyst Estimates | MarketWatch

BZH SEC Filings

5 Year Financials: Earnings are highly erratic, moving on an annual basis from net income to net loss and back again to net income. 

Annual Report for the Fiscal Year Ending 8/30/20 at page 25 

Investment Category: Lottery Ticket Basket

Profit Snapshot: +$50.49 

Item #  1.B. Bought 5 BZH at $12.95 (11/11/20 Post) 

The only prior trade was a 10 share lot realizing a $77.59 profit. 

The optimal time to own was when homebuilders experienced a long period of consecutive annual earnings. BZH produced a 626.14% return between 6/1/2000 to 1/9/2007. DRIP Returns Calculator | Dividend Channel The total return starting on 1/10/2007 through 5/21/2021 was -89.2% (starting price of $223.75 adjusted for reverse stock splits). 

Last Earnings Report (Fiscal Second Q/E 3/31/21): SEC Filed Press Release 

Diluted E.P.S. = $.81, up from $.35 year-ago quarter


M. Pared KEY-Sold Fractional Shares purchased with dividends at $22.96


Quote: 
KeyCorp (KEY)
Investment Category: Regional Bank Basket Strategy

Profit Snapshot = +$3.64 (.403 share)


Average cost per share after pare: $12.18 (15 shares)

Snapshot Intraday 5/20/21 after pare

AC was reduced from $12.23 

Dividend:  Quarterly at $.185 per share ($.74 annually), last raised from $.17 effective for the 2019 third-quarter payment. 

Stock Splits & Dividends

As with most regional banks, the dividend was not raised in 2020 due to the credit issues and uncertainties created by the pandemic.  

Yield at New AC per share = 6.08%

Last Ex-Dividend: 5/28/21

KeyCorp Declares Quarterly Cash Dividend On Common Shares And Preferred Stocks

I have turned off dividend reinvestment. 

Last Earnings Report (Q/E 3/31/21): KeyCorp Reports Record First Quarter 2021 Net Income Of $591 Million, Or $.61 Per Diluted Common Share

NIM: 2.61%, down from 3.01% in the 2020 first quarter.

Cash Efficiency Ratio: 60.3%

ROA: 1.44% 

ROE: 14.98%

ROTE: 18.25%

NPL Ratio: .72%

Charge Off Ratio: .46%

Coverage Ratio: 222%

Tangible Equity to Tangible Assets: 7.5%

Total Capital Ratio: 13.4%

Credit Loss Provision: Net benefit of $93M

Loan to Deposit: 73.1%

Last EliminationItem # 1 Sold 140 KEY at $11.8 (7/27/2013 Post)(profit snapshot = $429.32) 

KEY Realized Gains to Date: $738.95

N. Pared HOPE-Sold 17.644 at $15.59


Quote: Hope Bancorp Inc. 

"Hope Bancorp, Inc. is the holding company of Bank of Hope, the first and only super regional Korean-American bank in the United States with $17.2 billion in total assets as of March 31, 2021. Headquartered in Los Angeles and serving a multi-ethnic population of customers across the nation, Bank of Hope operates 53 full-service branches in California, Washington, Texas, Illinois, New York, New Jersey, Virginia and Alabama. The Bank also operates SBA loan production offices in Seattle, Denver, Dallas, Atlanta, Portland, Oregon, New York City, Northern California and Houston; commercial loan production offices in Northern California and Seattle; residential mortgage loan production offices in Southern California; and a representative office in Seoul, Korea."

SEC Filings

2020 Annual Report

HOPE Analyst Estimates | MarketWatch

I have been selling my highest cost lots. 

Investment Category: Regional Bank Basket Strategy

Profit Snapshot:  $34.63 (5/21 sale only)


New AC per share this account: $10.4 (34+ shares): 

Snapshot Intraday on 5/21/21 after pare

Dividend: Quarterly at $.14 per share ($.56 annually), last raised from $.13 effective for the 2018 second quarter payment. 

Yield at New AC = 5.38%

Last Earnings Report (Q/E 3/31/21): SEC Filed Press Release 

Last Sell Discussion:  Item # 1.H.  Pared HOPE in Fidelity Taxable-Sold 22 at $15.52 and 14 at $15.96 (4/1/21 Post) 

O. Eliminated AVK-Sold 10 at $19.52

Quote: Advent Convertible & Income Fund Overview

Profit Snapshot: $64.34  (5/28/21 sale only)


Data Date of 5/28/21 Trade

Closing Net Asset Valuer per share: $20.27

Closing Market Price per share: $19.49 

Discount: -3.85%

Average 5 Year Discount: -10.98%

Sourced: AVK-CEF Connect

I discussed this leveraged CEF in my last post and have nothing further to add. Item # 2.O.(5/28/21 Post) 

P. Added 5 TAK at $17.12; 5 at $16.73



Quote: 
Takeda Pharmaceutical Co. Ltd. ADR

1 ADR = .5 ordinary share

I discussed this company in my 5/23/21 post and have nothing substantively to add here. Item # 2.H. Bought 10 TAK at $17.22 (5/23/21 Post) 

I will continue to average down in small lots until I hit 100 shares. 

Current Position: 20 shares

Average Cost per share: $17.07

The dividend has been at 180 ¥ per share annually or 90¥ per ADR share. Share Data | Takeda

That would translate to about US$.82 per share at today's current exchange rate. 

A semi-annual payment was made in March according to Morningstar. Takeda Pharmaceutical Co Ltd (4502) Dividends - XTKS | Morningstar

Q. Received Proceeds from GATX for early call of Baby Bond GMTA-Schwab Taxable


The coupon was 5.625% paid on a $25 par value. GATX had the option to redeem at par value + accrued and unpaid interest on or after May 30, 2021. The issuer did not waste any time in calling this bond when it had the right to do so.  

Payment of Accrued Interest: $7.03

Investment Category: Exchange Traded Baby Bonds, a subcategory of Exchange Traded Bonds

Profit Snapshot: +$166.77


Discussed at  Item # 4.A. Restarted GMTA-Bought 10 $18.21; 10 at $15.21 (4/18/20 Post) 

As with other exchange-traded baby bonds, there was no make-whole provision in the prospectus that would have prevented an early call due to the penalty associated with it. 

A make-whole payment is generally the sum total of all interest payments until the original maturity, which was 5/30/2066 for GMTA, and the principal amount discounted to present value using the yield of comparable U.S. treasury maturity (or a slow discount rate which juices the premium payment) 

Call protection was for 5 years after issuance.  

R. Finished Paring TPVG in Fidelity Account-Sold last fractional share

Quote: TriplePoint Venture Growth BDC

TPVG SEC Filings

Profit (.461 share) = $2.01 (6/1/21 sale only)


New AC per share this account = $6.22 (39 shares)

Snapshot Intraday 6/1/21 after pare

Dividend: Quarterly at $.36 per share  (regular only)

TPVG Dividend History | Nasdaq

I have turned off dividend reinvestment. 

Yield at AC = 23.15%

Next Ex-Dividend: 6/15/21

Last Substantive Buy DiscussionItem # 3.B. Added 5 TPVG at $11.1; 5 at $10.7; 5 at $8.2; 5 at $6.92; 2 at $5.35; 2 at $4.45; 2 at $4; 2 at $3.5; 2 at $2.99; 5 at $4.96  (4/11/2020 Post) 

I have nothing to add to my recent discussion. Item # 1.L. Sold 5 TPVG at $15.67 in Schwab Taxable and Item #1.M. Sold 11 TPVG at $15.67-highest cost shares in Fidelity Taxable(5/16/21 Post) 

I own a few shares in Roth IRA accounts and 13 shares in my Vanguard taxable account with an average cost of $5.32 per share (yield at AC = 27.07%):  


Those purchase prices are something to keep in mind when evaluating potential downside risks for BDCs. They did crash and burn last year and in 2008. 

DisclaimerI am not a financial advisor but simply an individual investor who has been managing my own money since I was a teenager. In this post, I am acting solely as a financial journalist focusing on my own investments. The information contained in this post is not intended to be a complete description or summary of all available data relevant to making an investment decision. Instead, I am merely expressing some of the reasons underlying the purchase or sale of securities. Nothing in this post is intended to constitute investment or legal advice or a recommendation to buy or to sell. All investors need to perform their own due diligence before making any financial decision which requires at a minimum reading original source material available at the SEC and elsewhere. A failure to perform due diligence only increases what I call "error creep". Stocks, Bonds & Politics: ERROR CREEP and the INVESTING PROCESS Each investor needs to assess a potential investment taking into account their personal risk tolerances, goals, and situational risks. I can only make that kind of assessment for myself and my family members. 

32 comments:

  1. Novo Nordisk A/S ADR (NVO)
    AFTER HOURS $86.00 +5.05 +6.24%
    Light Volume: After Hours Volume: 12.5K
    Last Updated: Jun 4, 2021 at 6:07 p.m. EDT
    https://www.marketwatch.com/investing/stock/nvo?mod=over_search

    The FDA approved NVO's weight loss drug.


    Given the light volume, the current price in after hours trading may not be indicative of how investors will respond to this positive, though expected news.

    I own about 10 shares and have discussed the purchase of 4 here.


    Item # 1. E. Started NVO-Bought 1 at $71.3; 1 at $70.3; 1 at $68.9; 1 at $68.3: https://tennesseeindependent.blogspot.com/2021/03/bhb-cc-cxp-cznc-dpg-fdus-fhb-flo-fnb.html

    ReplyDelete
    Replies
    1. NVO is now trading in after hours at $90 bid/$92 ask.

      After checking my accounts, I own 10 shares and discussed the purchase of 4.

      I entered a limit order to sell 2 of the 10 at $92.

      Article on FDA's approval:
      https://www.cnbc.com/2021/06/04/fda-approves-obesity-drug-that-helped-people-cut-weight-15percent.html

      Delete
    2. I hadn't bought in. But I suspect it's not too late! Will need to keep the chart in front of me for the next few weeks.

      Delete
    3. Land: NVO traded as high as $97.79 in after hours but finished at $82.99, up +$2.04 in after hours, a more reasonable response to the expected approval. I do not have any interest in selling at that price. The drug will be a blockbuster but the current P/E is well above other major drug company stocks.

      Given the light volume in after hours (33.3K), no conclusion can be drawn about how NVO will respond on Monday. Average daily volume during regular trading is over 872K.

      Delete
    4. Interesting. One of the common responses to good news. First a spike then comes back to a small gain.

      Your sell 2 at 92 order must of filled.

      P/E is bloated. (Joke needed) It needs to take some of NVO's drug to loss and get into shape.

      Delete
    5. Land: I missed a fill by failing to act quick enough when I saw the spike. The stock was on its way down from $97+ when I placed the order.

      My youngest nephew, who just completed his third year of medical school at Northwestern, opined that the drug was a game changer for weight loss. He by the way has now decided to take a year off from medicine to get an MBA from Northwestern. His grandfather, my father, who was told to finish high school by my mother after taking a year off to work during the depression, would not understand the need for so much education.

      Delete
    6. Lol, that is a lot of education.

      He's getting an MBA in a year? I thought those were several years programs. I doubt he'll ever want for a job.

      I'm sure your dad was thankful over the years for your mom's advice.

      Delete
    7. Land: He has started the program and will receive an MBA in one year. Normally, it is a 2 year program.

      My mother was not offering "advice". It was a shape up or ship out kind of deal.

      Delete
    8. Ah, bet he appreciated it looking back. I wonder how she knew to value the education, over the immediate job opportunities.

      He must be sharp.

      Delete
  2. Dropbox, Inc. (DBX)
    Friday's Close: $28.50 +$0.30 (+1.06%)

    The WSJ reported last week that Elliott Management had acquired "more than" a 10% stake in DBX and was in discussions with the company.

    Article: 6/2/21
    https://www.thestreet.com/investing/dropbox-jumps-on-news-of-elliott-management-stake

    The shares closed at $26.81 on 6/1. Volume accelerated to 17.39M shares on 6/2, up from 3.889M the previous day, with a close at $27.86.

    I have not seen yet the required disclosure filed with the SEC.

    I currently own 4 DBX shares in my Schwab taxable account with a $19.04 AC per share and 9 shares in my Fidelity taxable with an AC of $18.77.


    The position is classified as a Lotto.

    Last Buy Discussions
    Item # 2.D. Added to DBX-Bought 1 at $18.1; 1 at $17.79:
    https://tennesseeindependent.blogspot.com/2020/11/bcbp-bmoprs-cio-dbx-ddd-exg-fdus-glq.html

    Item # 1.C. Started DBX as a Lottery Ticket-Bought 5 at $19.1; 1 at $18.87; 1 at $18.7
    https://tennesseeindependent.blogspot.com/2020/10/bdge-brkl-csco-dbx-ebtc-evrg-fivg-fncl.html

    ReplyDelete
    Replies
    1. I'd considered Dropbox but at that point decided it was too rich a valuation.

      Seems like it might continue to fly.

      Delete
  3. AMC Networks Inc. Cl A (AMCX)
    Last Close: $66.80 +$10.03 $17.67%

    Last Friday, this stock opened at $56.62 and spent the day climbing higher and continued to rise in after hours trading.
    https://www.marketwatch.com/investing/stock/amcx?mod=over_search


    I own 15 shares with an AC of $21.85 and an unrealized gain of $674.26 at last Friday's closing price.

    This stock has been a bungee jumper since I bought shares last September.

    Item # 1.I.Started AMCX-BOUGHT 1 at $25.02; 1 at $23.75; 1 at $23.39; 1 at $23.15; 1 at $23; 1 at $21.99; 2 at $21.9; 3 at $21.4; 2 at $21.17; 2 at $20.9; 1 at $20.32 and Sold 1 at $25.12:
    https://tennesseeindependent.blogspot.com/2020/09/aiq-amcx-cxp-cznc-fbnc-fcpvx-mgc-ppt.html

    I have only a few observations.

    (1) The stock is still selling at less than a 10 P/E using the $7.45 average E.P.S. estimate for 2021.

    (2) Again, the concern is what happens after the Walking Dead franchise series ends in 2022. There are offshoots that are continuing or will start.

    https://www.nytimes.com/2020/09/09/arts/television/walking-dead-ending-spinoff.html

    (3) Given its relatively small size, AMC Networks is a potential acquisition candidate. The market cap is only 2.82B according to Marketwatch at last Friday's closing price of $66.8.

    ReplyDelete
    Replies
    1. Still under 10 P/E? Humm. I put on Walking Dead for a few mins a couple times. I think that was it. I didn't last. But if they found a formula, they often then make more items that work.

      Delete
    2. Land: AMC's first big blockbuster was "Mad Men" (2007-2015). There were concerns about how the company would replace that show. "Walking Dead" premiered in 2010 and will last until 2022. "Fear the Walking Dead", a spinoff, premiered in 2015 and will go on. There is already another spinoff called the "The Walking Dead:World Beyond".

      AMC Networks is a collection of cable channels that can now be accessed with a monthly streaming subscription. The company is off to a good start in its streaming service, topping 6M subscribers by year end.

      https://www.hollywoodreporter.com/business/business-news/amc-networks-earnings-report-streaming-subscribers-4139226/

      The other networks include Shudder, BBC America, IFC and Sundance.

      One of the attractions IMO is that company bought back 26.6% of the stock last year at
      $23.2.
      https://www.globenewswire.com/news-release/2020/10/21/2111727/0/en/AMC-Networks-Announces-Final-Results-of-Modified-Dutch-Auction-Tender-Offer.html

      Notwithstanding the good free cash flow and earnings numbers, the short position has remained high after that buyout.

      YF has the short position at 35.44% of the float as of 5/14/21:

      https://finance.yahoo.com/quote/AMCX/key-statistics?p=AMCX

      The stock has been at times subject to short squeezes but the shorts still have conviction as shown by the data.

      Delete
    3. It's hard to be a hip buyer of new businesses... when I have no idea about these shows. I've never even heard of "Mad Men."

      26.6% buy back in the middle of the pandemic mess is a nice move. They appear to be savvy management.

      Delete
  4. I'm hearing that Yellen got agreement from 8 countries to a minimum corporate tax rate. Some larger international companies may stop climbing for a little while.

    ReplyDelete
    Replies
    1. Land: They still need to pass laws to implement the minimum rate, and then there are an array of issues on how to prevent tax avoidance through corporations using non-complying countries. Several countries have between zero and 15% corporate tax rates. Republicans will probably oppose since they do not want to bite the hand that feeds them.

      Delete
    2. The article I'd read was all glowing and excited about how it will change the market. But those slowdown obstacles are much more like what I'd expect!

      Particularly the article said GOP wouldn't object because it'd be pro-business (by supporting USA businesses). I think it was NPR's site. I wondered what planet they were on. They didn't notice the permanent GOP road block at the Senate?

      Delete
  5. I noticed earlier this morning that biotech stocks abruptly turned higher in response to the FDA's approval of BIIB's Alzheimer's disease drug aducanumab. This is a controversial decision, but will at least for now lift this sector.

    BIIB has been halted for trading for awhile now. But may open about 45% higher.

    https://www.fool.com/investing/2021/06/07/biogen/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

    The last trade was at $286.43 before the halt at around 10:44 A.M. E.D.T.
    https://finance.yahoo.com/quote/BIIB?p=BIIB&.tsrc=fin-srch


    Biotech ETFs are trading that own BIBB.

    The largest is IBB:

    iShares Nasdaq Biotechnology ETF (IBB)
    $159.89 +$6.87 (+4.49%)
    As of 12:56PM EDT.
    https://finance.yahoo.com/quote/ibb/?p=ibb

    The price probably reflects already an estimation of where BIIB will open.

    BIIB had a 3.63% weighting as of 6/4/21 in IBB:
    https://www.ishares.com/us/products/239699/ishares-nasdaq-biotechnology-etf

    ReplyDelete
    Replies
    1. Biogen Inc. (BIIB)
      $405.79 $119.65 +41.82%
      Last Updated: Jun 7, 2021 at 2:21 p.m. EDT
      https://www.marketwatch.com/investing/stock/biib?mod=over_search

      It looks like trading resumed around 1:30 P.M. E.D.T at around $446, quickly trading up to $458 and has been drifting down since then.

      Delete
  6. Organon & Co. (OGN)
    $31.42 -$2.73 -7.99%
    https://www.marketwatch.com/investing/stock/ogn?mod=over_search

    OGN was spun out of MRK last week and has faired poorly since it started regular trading last week.

    MRK shareholders received .1 OGN share for each MRK share. Fractional shares were not paid in stock but in cash.

    I owned MRK on the distribution date in 5 accounts but did not own 10 shares in any single account. So I have been receiving cash. I totaled the cash payments up and could almost buy 2 shares with the sum, so that is what I did today, purchased at $31.2. This is a placeholder which is not currently generating any interest.

    I suspect the downtrend is being caused by market dynamics as institutional owners of Merck stock are just unloading the OGN shares received in the spinoff.

    OGN had to pay about $9B to MRK and that payment was financed with new debt. OGN is large enough to have already been added to the S & P 500.

    What I know about the company is limited to the information disclosed by it in this SEC filing:

    https://www.sec.gov/Archives/edgar/data/1821825/000119312521140380/d56612dex991.htm

    ++

    The price action today in NVO and BIIB highlight the difference between an expected FDA decision and unexpected one.

    Novo Nordisk A/S ADR (NVO)
    $81.20 +$0.25 +0.31%
    https://www.marketwatch.com/investing/stock/nvo?mod=over_search

    Good news is already baked into NVO's multiple IMO. What may not yet be baked into the price is far better than expected sales of the weight loss drug.

    NVO barely budged from its Friday's close. FDA approval of its weight loss drug, which will likely be a major blockbuster based on what is known now, was announced after the close on Friday.

    BIIB on the other hand finished up $109.71, closing at $395.85.

    ReplyDelete
    Replies
    1. Up 40%? That's incredible. I missed it, but I'll get the hang of catching things.

      Alzheimer's is a factor. It's so in need of help. So even if less than ideal, it will get personal excitement that will add to the market's.

      Will be interesting to see if it continues a climb tomorrow, or that was the top of interest in it.

      Still rather surprising it wasn't an expected approval... there's usually insider leakage.

      You picked the right sector for pops and growth in an otherwise awkward market.


      Delete
  7. The BLS will be releasing tomorrow mornings its CPI report for May. Another hot inflation number is expected but is inflation even a relevant factor in setting rates. My answer is that inflation is irrelevant when the CBs are setting rates across the maturity spectrum without regard to inflation and inflation expectations.

    Inflation may at some point become relevant only if the CBs including the FED react by abandoning all rate manipulation monetary policies and allow the Bond Ghouls and a free market to decide the appropriate level for intermediate and longer term rates. All CBs would also need to end QE, ZIRP and negative benchmark rates, with the FF and other benchmark rates set near the inflation rate.

    Today, the yield on the ten year treasury fell again, closing down 3 basis points to 1.5%, hardly a sane reaction to hot inflation numbers unless the sane goal is to earn an annual average negative real rate of return over a ten year period before taxes make it worse.

    The ten year TIP closed at a negative -.82 yield, creating a breakeven inflation rate of 2.32, the annual average CPI for the next years necessary for the buyer of that TIP to break even with the buyer of a 1.5% nominal 10 year treasury.


    https://www.treasury.gov/resource-center/data-chart-center/interest-rates/Pages/TextView.aspx?data=realyield

    I thought it was bizarre that the ten year TIP had a similar negative yield in 2012, so I sold them.

    1. Sold 3 Treasury Inflation Protected Bonds at 120.45 Last Tuesday-ROTH IRA
    http://tennesseeindependent.blogspot.com/2012/05/sold-3-tip-bonds-maturing-in-2019-at.html

    The yield at my sale's price was -.89%. I booked a $838.37 profit on those 3 bonds, having bought the bonds at auction in 2009:

    Item # 4
    https://tennesseeindependent.blogspot.com/2009/07/sold-pepsico-sold-general-millssold-12.html

    I bought below par value with a coupon at close to 2%.

    ReplyDelete
    Replies
    1. There definitely feels like inflation. This BLS# was supposed to be a one off last time. And only start reacting this time. (Though usually the slow cooking happens and there isn't reaction after all.)

      Does inflation only matter to the market via rates? More expensive goods... doesn't that have a neg effect on anything? People's ability to do discretionary spending, anything?

      I'm not convinced the Fed will stick with pure zirp if there's inflation. They shouldn't break 2%. But I'm not seeing a sharpness about their jawboning & actions. So I'm not counting on your real, rational, assessment to happen. As in, they could push up rates while it mucks with the US gov't's debt interest.

      Was there a special event that caused the end of day narket worry... or just looking forward to tomorrow's news? I'm assuming the later.

      My heat pump included inflation. There's shortage of whole units and repair parts. The were talking to each other, something about stealing mine out from someone's else's wait list. I'm guessing about 8% from last year pre-covid. Part of my calculations on buying was to assume another 10% increase is happening in the next year or two on heatpumps.

      I worry about covid in the house. But blew the floor they were on...'s air out the window. Stayed in an upstairs room with door closed. Now have unit on but windows open in that upstairs room. But can feel the air - it's so nice compared to grimy humidity. My hair was getting fluffier and wider than a zoom screen. (So many cultures wear head coverings... so you didn't have to do your hair before heading to the central open air market each day.)

      NVO still climbing. But not outrageously so. Looks like the held.

      BIIB - has kept that huge gap up. There's a huge gap up in late 2020. Then back to baseline. I wonder if this climb will hold?



      Delete
    2. Land: The annual CPI rate was at 4.2% through April.

      https://www.bls.gov/news.release/cpi.nr0.htm

      There was a slight decline in May 2020.
      https://www.bls.gov/news.release/archives/cpi_06102020.htm

      The FED chooses to deemphasize CPI and instead focuses on PCE inflation, which increased 3.6% through April 2021.

      https://www.bea.gov/data/personal-consumption-expenditures-price-index


      The annual average CPI predicted in the 10 year TIP breakeven spread is not a headwind for stocks. There is a net benefit since that asset class is at least capable of producing real rates of return which is not the anticipate case for a ten year treasury purchased today and held onto maturity. The suppression in interest rates below the inflation rate and excessive money creation have contributed to the parabolic rise in stock prices.

      Consumers are paying higher prices at the gas pump but only compared to the abnormally low prices prevailing during the spring and summer of 2020.

      Wages are increasing above the recent historical average.

      The tiny dip in major market averages late in the day is meaningless. What is meaningful is the current level with the S & P 500 closing at 4,219.55, down .18%.

      Regional banks were hit by the decline in interest rates.

      Biotech stocks were probably my best performing sector today.

      I mentioned in an earlier comment buying 2 shares of BMRN and I am now up to 5. I will be discussing that one in my next post. I did not see any news for its pop today.

      BioMarin Pharmaceutical Inc.
      $82.05 +3.29 +4.18%
      https://www.marketwatch.com/investing/stock/bmrn?mod=over_search

      OGN, the spinoff from Merck, may be at below zero by month's end assuming it continues its rate of descent. I am buying 1 and 2 share lots.

      https://www.marketwatch.com/investing/stock/ogn?mod=over_search

      E.P.S. was $5.9 in 2020 but Merck saddled it with $9B in debt to fund a pre-spinoff distribution.

      https://www.barrons.com/articles/organon-stock-51623032799

      Merck is probably better off with the $9B now than continued ownership of what is now Organon's businesses unless the company comes up with something new and lucrative.

      ++

      As to heating/air conditioning units, when I had a major part goes bad, I replaced it once and regretted the decision since the repaired old unit did not last long enough to justify the expense.

      I will take into account the age of the unit and the cost of the repair. About 2 years ago, I spent a worthwhile sum replacing some wiring. Any new repair that costs over $200 now will likely result in a new unit purchase given the age at over 12 years.

      Delete
  8. "The suppression in interest rates below the inflation rate and excessive money creation have contributed to the parabolic rise in stock prices."

    That was in line with my reaction... that ot oh, now the rally is back on in order to chase inflation.

    But I think Fed is expected not to do much. Even by the Fed. And then they'll do something just a hair too much. It's my cynical expectation, not based on any concrete info.

    ----

    I wound up with the same impression that an old unit should be replaced. My dad thought as long as the compressor works, do the repair. But 1) it's old freon that's getting expensive to access 2) it has a slow leak 3) newer has more efficiency. That efficiency puts it the final way over the top.

    By calculation I could pay slightly ($40) a year less by keeping the old... IF it lasted 5-7 more years (or more).

    Meanwhile it's losing enough old type freon to need a fillup every 10 years (or sooner, I haven't checked sooner.)

    So max gain was it lasting between 5-7 up to 10 years.

    Old enough that if I sell the house, I'd be better off replacing than giving the house a very old image. So it wasn't that if I moved in a few years I'd have avoided the replacement cost.

    The problem with replacing these units is that it's a lot of money so you want to shop wisely, but by the time you do so - you're without heat or A/C.

    I got lucky. Found a fair priced contractor who could do it soon. So that finalized the decision.

    I used to have "an HVAC" guy. But he re-married. His wife took over and said everyone was taking advantage of him. So much for sane interactions. Since then I keep getting the "short female and for men, the we see a windfall coming" prices."

    So this is done. And without weeks of total stress or craziness researching.


    ReplyDelete
  9. Bristol Myers Squibb (BMY)
    $67.35 $1.94 +2.97%
    Last Updated: Jun 10, 2021 at 12:30 p.m. EDT

    Drug stocks have been so far my best performing sector this week with decent percentage gains across the board.

    BMY did report earlier today that its Phase 3 study of Breyanzi as a second-line treatment for relapsed or refractory large B-cell lymphoma met its primary and key secondary objectives.

    https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-TRANSFORM-Trial-Evaluating-Breyanzi-lisocabtagene-maraleucel-Versus-Chemotherapy-Followed-by-Stem-Cell-Transplant-in-Second-line-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspx

    This drug was approved by the FDA last February
    "for the treatment of adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B."

    ReplyDelete
  10. The BLS reported that CPI rose 5.4% Y-O-Y through May 2021. Core CPI was up 3.8%.

    https://www.bls.gov/news.release/cpi.nr0.htm

    Interest rates declined in response, which is just another piece of evidence that inflation is basically irrelevant when setting interest rates and that can only happen when Central Banks are controlling rates without regard to inflation and inflation expectations across the maturity spectrum.

    The ten year treasury yield fell 5 basis points today, closing at 1.45%.

    https://www.treasury.gov/resource-center/data-chart-center/interest-rates/Pages/TextView.aspx?data=yield

    The breakeven inflation rate for the 10 year TIP closed at 2.35%. The yield on the ten year TIP closed at a negative .9%.

    https://www.treasury.gov/resource-center/data-chart-center/interest-rates/Pages/TextView.aspx?data=realyield

    Corporate bonds rallied slightly more than U.S. treasuries.


    iShares 7-10 Year Treasury Bond ETF (IEF)
    $115.78 +$0.41 +0.36%
    https://www.marketwatch.com/investing/fund/ief?mod=over_search

    iShares Investment Grade Corporate Bond ETF (LQD)
    $133.56 +$0.60 +0.45%
    https://www.marketwatch.com/investing/fund/lqd?mod=over_search

    LQD has an effective duration of 9.56 years:
    https://www.ishares.com/us/products/239566/ishares-iboxx-investment-grade-corporate-bond-etf

    IEF has an effective duration of 7.94 years:
    https://www.ishares.com/us/products/239456/

    +++

    W.P. Carey (WPC) had a successful stock offering this week raising approximately $454.6M.

    https://www.prnewswire.com/news-releases/w-p-carey-inc-announces-closing-of-public-offering-of-common-stock-301310330.html

    The stock dipped from $77.82 to $76.42 in response, but is now back up to $77.55. Both the dip and recovery indicate interest among institutional investors even at higher prices prevailing between January-May 2021. The stock was trading at less than $75 in mid-May 2021 and closed at $68 on 1/3/21.


    https://finance.yahoo.com/quote/WPC/history?p=WPC


    ReplyDelete
  11. CRISPR Therapeutics AG (CRSP)
    $129.00 +$5.29 +4.28%
    Last Updated: Jun 11, 2021 at 10:06 a.m. EDT

    Today's pop is in response to this press release:

    “The data presented today in 22 patients are impressive in both the consistency and durability of effect. These results add to the growing body of evidence that CTX001 may hold the promise for a one-time functional cure for sickle cell disease and beta thalassemia. We are working with urgency to complete enrollment and look forward to finalizing regulatory discussions and moving towards filing.”

    https://www.businesswire.com/news/home/20210611005069/en/

    +++

    Vertex owns 60% of that compound and paid dearly for that interest.

    That stock is being slammed today based on another drug failing in a Phase 2 trial.

    Vertex Pharmaceuticals Inc.
    $199.10 -$17.67 -8.15%
    Last Updated: Jun 11, 2021 at 10:10 a.m. EDT
    https://www.marketwatch.com/investing/stock/vrtx?mod=over_search

    Press Release on VX-864
    https://www.businesswire.com/news/home/20210610005939/en/

    I will be discussing VRTX in my next post. I now own 2+ shares in my Fidelity account. And, I am not exactly swinging for the fences with a $50 buy limit order below the current price.

    ++

    I own 2 shares of Incyte (INCY) in my Fidelity account and it received negative news today as well:

    "Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis"
    https://www.businesswire.com/news/home/20210611005030/en/Incyte-Announces-U.S.-FDA-Has-Extended-the-New-Drug-Application-Review-Period-for-Ruxolitinib-Cream-for-the-Treatment-of-Atopic-Dermatitis

    Incyte Corp. (INCY)
    $83.49 -$4.04 -4.62%

    Of those 3 stocks, my largest $ exposure is to CRSP, and all of the positions are light years below insignificant for me.

    ReplyDelete
    Replies
    1. The $50 VRTX buy order was filled at $196.44, bringing me up to 2.55 shares. The stock is currently trading under that price.

      Delete
    2. Those are interesting things happening with the drug stocks.

      CRSP - still have my eye on. Either it breaks to the upside as the market climbs. Or continues in this range.

      The inflation measures are begining to worry me. I have enough funds that with returns inside expected ranges, and SSI continuing to exist... I won't be opulent, but if I get 2% over inflation, can live indefinitely on the funds by the time of retirement.

      The current inflation without return puts that at risk. I need to get into div stocks. Or growth.

      And that's what a lot of people are now waking up and realizing.

      Which means this market can't go down. No until FED reacts to rates. It won't want to it. It can ill afford to. Rates are no longer linked to insurance. But they'll be tempted. So down the road, that's coming.

      For now it's confusing. I need to invest... in a market that's struggling.

      Delete
  12. I have published a new post:
    https://tennesseeindependent.blogspot.com/2021/06/amcr-bmrn-bmy-cgbd-csco-fcx-ffhprgca.html

    ReplyDelete